Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the interest of the use of EMDR (Eye Movement Desensitization and Reprocessing) psychotherapy in the management of psychotic disorders, in particular schizophrenic disorders.


Clinical Trial Description

Since 2015 more and more studies conducted by researchers, especially Dutch and English, are interested in the use of EMDR (Eye Movement Desensitization and Reprocessing) for other pathologies such as bipolar disorder, unipolar depression, anxiety disorders, psychotic disorders, substance use disorders and chronic pain. These studies show that EMDR appears to be a technique that is both effective, capable of significantly improving symptoms, and without risk for patients, while respecting the protocol and the clinical stabilization provided during the procedure. To date, the use of EMDR for the management of psychotic patients has not been the subject of any prospective study in France and the authors' conclusions converge on the fact that it is essential to carry out more research on the subject. For this, the investigators wish to evaluate the effect of EMDR on the management of patients with schizophrenic disorders, on the basis that this psychotherapy would improve their quality of life (improvement of all the specific scores used in psychiatry). : PANSS, DES, HAD and WEMWBS scales). Finally, the investigators believe that it is relevant to assess the benefit of EMDR six months after hospitalization of patients, in order to measure the maintenance of this efficacy in the medium term ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05164289
Study type Observational [Patient Registry]
Source Centre Hospitalier René Dubos
Contact
Status Terminated
Phase
Start date December 10, 2021
Completion date April 27, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04608032 - Neuropsychological Assessment of Remediation for Cognitive Impairments in Schizophrenia N/A
Terminated NCT00660595 - Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose Phase 3
Completed NCT02655172 - Have a Good Grasp of the Worldthe World N/A
Completed NCT01606436 - A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia Phase 1
Completed NCT01729650 - Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor) N/A
Completed NCT02525315 - Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations Phase 2
Completed NCT00488319 - Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia. Phase 3
Completed NCT00088491 - Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia Phase 3
Completed NCT01279213 - Clozapine/Paliperidone Versus Clozapine/Placebo in Resistant Schizophrenia Phase 4
Completed NCT00600756 - Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone Phase 3
Completed NCT00572247 - The Psychiatric Rehabilitation Approach to Weight Loss N/A
Completed NCT00491569 - Sarcosine or D-Serine Add-on Treatment for Chronic Schizophrenia Phase 2
Completed NCT00328276 - Sarcosine (N-Methylglycine) Monotherapy for Schizophrenia Phase 2
Completed NCT00485823 - Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia Phase 4
Active, not recruiting NCT00161408 - Psychological Intervention for Relapse Prevention in First Episode Schizophrenia N/A
Withdrawn NCT00276263 - Sarcosine Preventive Therapy for Individuals At High Risk for Schizophrenia Phase 2
Completed NCT00088465 - Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder Phase 3
Withdrawn NCT02654405 - Sodium Butyrate For Improving Cognitive Function In Schizophrenia Phase 2/Phase 3
Completed NCT02544516 - Upside Down, Give me the Handle N/A
Completed NCT00960219 - D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia Phase 2